Biorad Medisys Announces Its Entry into the US Market with the Launch of its New Subsidiary Medtimo Inc.

Medtimo Inc. will help Biorad Medisys expand its market reach, and deliver healthcare solutions in US’ market

Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidiary Medtimo Inc. The move comes post Biorad Medisys’ completion of acquisition of business assets from ReShape Lifesciences, a w********** and metabolic health solutions, and its official rebranding to Medtimo Inc.

The investment is in line with Biorad Medisys’ intention of seeking growth in regulated markets by expanding its portfolio, enhancing its global reach and curating a sharpened product strategy. The new subsidiary will continue to deliver life-changing technologies to patients across the US and abroad.

Also Read: AiThority Interview with Dr. Petar Tsankov, CEO and Co-Founder at LatticeFlow AI

Medtimo will prioritize its portfolio around two core products: Lap-Band®, a minimally invasive solution for long-term w**********, and Stimel-03, a cutting-edge neurological rehabilitation therapy for stroke patients. This dual approach positions Medtimo to meet rising demand in both obesity treatment and stroke recovery. Biorad already has a tie-up for manufacturing US FDA approved Obalon® balloon in US and other markets and those efforts have been accelerated now.

“We are delighted to welcome Medtimo into the Biorad Medisys family,” said Jitendra Hegde, Managing Director, Biorad Medisys. “This expansion reflects our long-term commitment to the U.S. market and our confidence in Medtimo’s leadership team and our shared foundational ethos. Together, we are well positioned to accelerate innovation, broaden patient access to advanced therapies, and strengthen our presence in multiple critical areas of healthcare including obesity, type 2 diabetes and neurological rehabilitation.”

As part of Biorad Medisys, Medtimo Inc will leverage operational scale and international expertise to help drive product development and commercialization.

“This is a defining moment for our company, and I am grateful for Biorad Medisys’s commitment to our partnership,” said Paul F. Hickey, Chief Executive Officer of Medtimo Inc. “With the strength and strategic support of Biorad Medisys behind us, Medtimo is poised to accelerate growth, bring innovative solutions to more patients, and unlock our full potential in the U.S. and global markets. The rebrand also marks the beginning of an ambitious new chapter for our company.”

Also Read: Developing Autonomous Security Agents Using Computer Vision and Generative AI